Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Jan;31(1):55–59. doi: 10.1128/aac.31.1.55

High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.

R H Barbhaiya, S T Forgue, W C Shyu, E A Papp, K A Pittman
PMCID: PMC174651  PMID: 3566239

Abstract

A high-pressure liquid chromatographic assay was developed for the quantitative analysis of a new cephalosporin, BMY-28142, in plasma and urine. The plasma method involved protein precipitation with acetonitrile and trichloroacetic acid followed by extraction of the acetonitrile into dichloromethane. After centrifugation, the organic phase was discarded, the aqueous solution was injected into a reverse-phase column, and peaks were detected at 280 nm. The urine method involved dilution of a urine sample with sodium acetate buffer (pH 4.25) and direct injection into the high-pressure liquid chromatography system. The assay validation data indicate that the assays for BMY-28142 in plasma and urine were specific, accurate, and reproducible. The analytical methods were applied to the determination of protein binding in human serum and to a pharmacokinetic study in rats. The results of the protein-binding study indicated that BMY-28142 was 16.3% bound to human serum proteins. In the pharmacokinetic study in rats, the maximum level in plasma of 38.7 micrograms/ml was achieved at 2.33 h after administration of a subcutaneous dose of 100 mg/kg. The levels in the plasma then declined with an elimination half-life of about 0.56 h. The mean values for the steady-state volume of distribution and total body clearance were 0.46 liters/kg and 11.9 ml/min per kg, respectively. The 0- to 24-h excretion of intact BMY-28142 in urine accounted for 88.6% of the dose.

Full text

PDF
56

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakar S. K., Niazi S. Simple reliable method for chronic cannulation of the jugular vein for pharmacokinetic studies in rats. J Pharm Sci. 1983 Sep;72(9):1027–1029. doi: 10.1002/jps.2600720915. [DOI] [PubMed] [Google Scholar]
  2. Benet L. Z., Galeazzi R. L. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979 Aug;68(8):1071–1074. doi: 10.1002/jps.2600680845. [DOI] [PubMed] [Google Scholar]
  3. Fuchs P. C., Jones R. N., Barry A. L., Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985 May;27(5):679–682. doi: 10.1128/aac.27.5.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kemmerich B., Warns H., Lode H., Borner K., Koeppe P., Knothe H. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother. 1983 Sep;24(3):333–338. doi: 10.1128/aac.24.3.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kessler R. E., Bies M., Buck R. E., Chisholm D. R., Pursiano T. A., Tsai Y. H., Misiek M., Price K. E., Leitner F. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics. Antimicrob Agents Chemother. 1985 Feb;27(2):207–216. doi: 10.1128/aac.27.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Murakawa T., Sakamoto H., Fukada S., Nakamoto S., Hirose T., Itoh N., Nishida M. Pharmacokinetics of ceftizoxime in animals after parenteral dosing. Antimicrob Agents Chemother. 1980 Feb;17(2):157–164. doi: 10.1128/aac.17.2.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Oie S., Gambertoglio J. G., Fleckenstein L. Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing. J Pharmacokinet Biopharm. 1982 Apr;10(2):157–172. doi: 10.1007/BF01062333. [DOI] [PubMed] [Google Scholar]
  8. Perrier D., Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci. 1982 Mar;71(3):372–373. doi: 10.1002/jps.2600710332. [DOI] [PubMed] [Google Scholar]
  9. Singhvi S. M., Heald A. F., Gadebusch H. H., Resnick M. E., Difazio L. T., Leitz M. A. Human serum protein binding of cephalosporin antibiotics in vitro. J Lab Clin Med. 1977 Feb;89(2):414–420. [PubMed] [Google Scholar]
  10. Vuye A., Pijck J. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin. Antimicrob Agents Chemother. 1985 Apr;27(4):574–577. doi: 10.1128/aac.27.4.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Warns H., Lode H., Harnoss C. M., Kemmerich B., Koeppe P., Wagner J. Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):235–240. doi: 10.1093/jac/12.suppl_a.235. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES